StockData

Burning Rock Biotech vs Caris Life Sciences

BNR and CAI side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BNR and CAI compare

Caris Life Sciences grew revenue faster over the last twelve months (61.5% versus 4.6% for Burning Rock Biotech).

Caris Life Sciences keeps more of each dollar of sales as profit, with a net margin of 9.2% compared with −10.3% at Burning Rock Biotech.

Caris Life Sciences scores higher on the StockData Score (7 against 4 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBNRCAI
Size and price
Market cap–$5.6B
Share price$12.50$19.94
Change, 1 year6.5%−16.4%
Change, 5 years−90.9%–
Beta (5Y)2.522.53
Employees6671,846
StockData Score
Total score47 (better)
Valuation score00
Growth score11
Performance score13 (better)
Health score23 (better)
Dividend score00
Valuation
P/S–5.4×
P/B–8.8×
EV/EBITDA–36.5×
P/FCF–195×
FCF yield–0.51%
Fair value–$10.35
Margin of safety–−92.6%
Growth
Revenue growth (TTM)4.6%61.5% (better)
Revenue growth, 5Y average4.6%–
Profitability
Gross margin74.7%–
Operating margin−10.2%13.4% (better)
Net margin−10.3%9.2% (better)
FCF margin−6.2%2.8% (better)
Return on equity−9.9%17.2% (better)
Return on invested capital−72.5%26.8% (better)
Financial health
Debt / equity0.00 (better)0.61
Net debt / EBITDA–1.79
Interest coverage–3.3×
Current ratio2.996.71 (better)
Altman Z-score–4.73
Piotroski F-score56 (better)
Dividends and buybacks
Buyback yield–0.56%
Shareholder yield–0.56%
Ownership
Held by institutions1.8%54.5%
Held by insiders19.0%64.1%
Insider net buying, 12 months$11.6M (better)−$27.4M
Superinvestors holding–2
Short interest, % of float–11.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.